Advertisement

Serum Level of HLDF24 Peptide as an Objective Marker of Prehypertension

The concentrations of the key factors of molecular pathogenesis of prehypertension (angiotensin II, HLDF24, S100b, endothelin, autoantibodies to these molecules, and VEGF) were analyzed in subjects with optimal BP (<120/80 mm Hg) and prehypertension (120-139/80-89 mm Hg). Comparative and correlation analysis of the levels of these molecules was performed. A statistically significant decrease in HLDF24 level in prehypertension in comparison optimal BP was observed. Specific features and interactions between the studied factors in optimal BP and in prehypertension were studied. The mechanisms underlying the observed associations between serum concentration of HLFF24 and the development of prehypertension were discussed.

This is a preview of subscription content, log in to check access.

Access options

Buy single article

Instant unlimited access to the full article PDF.

US$ 39.95

Price includes VAT for USA

Subscribe to journal

Immediate online access to all issues from 2019. Subscription will auto renew annually.

US$ 199

This is the net price. Taxes to be calculated in checkout.

References

  1. 1.

    Barbarash NA, Kuvshinov DY. Prehypertension: synopsis and prospects. Fundament. Klin. Med. 2016;1(1):73-77. Russian.

  2. 2.

    Gapon MV, Dranitsyna SM, Minkevich NI, Gruden’ MA, Babichenko II, Kostanyan IA. Experimental model of hemorrhagic stroke: rabbit immunization with HL-60 promyelocytic cell differentiation factor. Bull. Exp. Biol. Med. 2006;141(2):272-274.

  3. 3.

    Clinical guidelines. Diagnostics and treatment of arterial hypertension. Kardiol. Vestn. 2015;10(1):3-30. Russian.

  4. 4.

    Elistratova EI, Gruden MA, Davidova TV, Sherstnev VV. Serum immunoboichemical markers in patients suffered with hypertension-induced cerebrovascular diseases. Patol. Fiziol. Eksp. Ter. 2011;(3):25-28. Russian.

  5. 5.

    Rzhevskii DI, Dranitsyna SM, Baidakova LK, Myrashev AN, Kostanyan IA. Hemodynamic effects of peptide fragments of differentiation factor HLDF. Bull. Exp. Biol. Med. 2006;141(6):704-707.

  6. 6.

    Senko OV, Morozov AM, Kuznetsova AV, Klimenko LL. Evaluating of multiple testing effect in method of optimal valid partitioning. Mash. Obuch. Analiz Dannukh. 2016;2(1):26-38. Russian.

  7. 7.

    Sherstnev VV, Gruden’ MA, Elistratova EI, Karlina VP, Kuznetsova AV, Ryzhova TV, Ryzhov VM, Sen’ko OV. Molecular markers of arterial hypertension in patients with normotony, pre-hypertension and hypertension. Bull. Exp. Biol. Med. 2015;158(5):604-606. doi: https://doi.org/10.1007/s10517-015-2816-x

  8. 8.

    Albarwani S, Al-Siyabi S, Tanira MO. Prehypertension: Underlying pathology and therapeutic options. World J. Cardiol. 2014;6(8):728-743.

  9. 9.

    Assadi F. Prehypertention: A Warning sign of future cardiovascular risk. Int. J. Prev. Med. 2008;5(Suppl. 1):S4-S9.

  10. 10.

    Egan BM, Stevens-Fabry S. Prehypertension — prevalence, health risks, and management strategies. Nat. Rev. Cardiol. 2015;12(5):289-300.

  11. 11.

    Huang Y, Su L, Cai X, Mai W, Wang S, Hu Y, Wu Y, Tang H, Xu D. Association of all-cause and cardiovascular mortality with prehypertension: a meta-analysis. Am. Heart J. 2014; 167(2):160-168.e1.

  12. 12.

    Liszka HA, Mainous AG 3rd, King DE, Everett CJ, Egan BM. Prehypertension and cardiovascular morbidity. Ann. Fam. Med. 2005;3(4):294-299.

  13. 13.

    Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, DePalma SM, Gidding S, Jamerson KA, Jones DW, MacLaughlin EJ, Muntner P, Ovbiagele B, Smith SC Jr, Spencer CC, Stafford RS, Taler SJ, Thomas RJ, Williams KA Sr, Williamson JD, Wright JT Jr. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71(6):e13-e115.

Download references

Author information

Correspondence to V. V. Sherstnev.

Additional information

Translated from Byulleten’ Eksperimental’noi Biologii i Meditsiny, Vol. 168, No. 9, pp. 268-271, September, 2019

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Sherstnev, V.V., Gruden, M.A., Karlina, V.P. et al. Serum Level of HLDF24 Peptide as an Objective Marker of Prehypertension. Bull Exp Biol Med 168, 305–308 (2020) doi:10.1007/s10517-020-04696-x

Download citation

Key Words

  • biomarkers
  • prehypertension
  • optimal BP
  • HLDF24 peptide